Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone

This article was originally published in The Pink Sheet Daily

Executive Summary

With a would-be competitor from Discovery Labs stalled at FDA, approved lung surfactant Curosurf sits at the center of equity, cash tie-up.

You may also be interested in...



Cornerstone Buys EKR Therapeutics To Expand Hospital Growth Strategy

Cornerstone gains two commercial products for the acute-care hospital setting, Cardene and Retavase, with the acquisition of EKR Therapeutics for $125 million upfront and potential milestones.

With Innovative Purdue Deal, Infinity Finds Shelter From The Storm

In exchange for ex-U.S. rights to the bulk of its early-stage oncology pipeline, Infinity has secured a cash runway into 2013.

Discovery Finalizing Surfaxin “Complete Response,” Eyes 2008 Approval

Firm plans response to May 1 “approvable” letter that addresses biological activity test criteria, lipid-related impurities.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel